36.70
-0.06(-0.16%)
Currency In USD
| Previous Close | 36.76 |
| Open | 36.8 |
| Day High | 37.14 |
| Day Low | 36.63 |
| 52-Week High | 46.48 |
| 52-Week Low | 21.18 |
| Volume | 1.02M |
| Average Volume | 2.21M |
| Market Cap | 5.82B |
| PE | 96.58 |
| EPS | 0.38 |
| Moving Average 50 Days | 31.67 |
| Moving Average 200 Days | 34.51 |
| Change | -0.06 |
If you invested $1000 in TG Therapeutics, Inc. (TGTX) 10 years ago, it would be worth $2,966.86 as of October 07, 2025 at a share price of $36.7. Whereas If you bought $1000 worth of TG Therapeutics, Inc. (TGTX) shares 5 years ago, it would be worth $1,200.13 as of October 07, 2025 at a share price of $36.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
GlobeNewswire Inc.
Sep 24, 2025 1:10 PM GMT
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 6 years of continuous treatme
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
GlobeNewswire Inc.
Sep 10, 2025 11:30 AM GMT
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
GlobeNewswire Inc.
Sep 08, 2025 11:30 AM GMT
Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimensNEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (u